Memantine in behavioral variant frontotemporal dementia: negative results

Area of Science:

• Neuroscience
• Clinical Neurology
• Pharmacology

Background:

• Behavioral variant frontotemporal dementia (bvFTD) is a neurodegenerative disorder characterized by profound changes in personality and behavior.
• Current treatment options for bvFTD are limited, highlighting the need for effective therapeutic strategies.

Purpose of the Study:

• To evaluate the efficacy and tolerability of memantine as a neuroprotective treatment for patients with behavioral variant frontotemporal dementia (bvFTD).

Main Methods:

• A national, randomized, double-blind, placebo-controlled (DBPC) Phase II trial was conducted.
• Participants (n=49) aged 45-75 with MMSE score ≥19 received memantine (10 mg bid) or placebo for 52 weeks.
• Primary endpoint: Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus). Secondary endpoints included NPI, FBI, MDRS, MMSE, DAD, and ZBI.

Main Results:

• No significant differences were observed between memantine and placebo groups for the primary endpoint (CIBIC-Plus, p=0.4458).
• Secondary endpoints also showed no significant differences, except for the Frontal Behavioral Inventory (FBI) score, which was lower in the memantine group (p=0.0417).
• Memantine was well-tolerated by patients throughout the study.

Conclusions:

• One-year memantine treatment did not demonstrate significant efficacy in improving overall clinical status or most behavioral symptoms in bvFTD patients compared to placebo.
• The observed reduction in FBI scores suggests a potential, albeit limited, benefit on specific behavioral aspects.
• Further multinational studies with larger cohorts are warranted to confirm these findings and explore memantine's role in bvFTD management.